Comparison of the clinical responses by the dosage of once or triple a week of MTX in patients with rheumatoid Arthritis

Comparison of the clinical responses by the dosage of once or triple a week of MTX in patients with rheumatoid Arthritis - POEM study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002175

Enrollment

Registered

2009-07-10

Start date

2009-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

MTX, once a week MTX, triple a week

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Rheumatoid Arthritis

Exclusion criteria

Exclusion criteria: Disqualified in patients with rheumatoid arthritis who judged by a doctor

Design outcomes

Primary

Measure	Time frame
DAS28(CRP)	—

Secondary

Measure	Time frame
EULAR Criteria Patient's Judgement	—

Countries

Japan

Contacts

Public ContactMotoriro Oribe

Oribe Rheumatism Clinic Rheumatology

oribe-riuma@iris.ocn.ne.jp097-513-7123

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026